SEC Tracker
Get the app

Spyre Therapeutics SYRE

Spyre Therapeutics reported a $96.12 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Net loss of $96.12 million for the three months ended Sep 30, 2026
  2. Diluted EPS of -$2.04 for the three months ended Sep 30, 2026
  3. Cash and equivalents of $82.73 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Spyre Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, Spyre Therapeutics, Inc. reported: Net income -$96.1 million.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Novavax NVAX public float $1.0B, Jun 30, 2025
  4. Harrow HROW public float $1.0B, Jun 30, 2025
  5. Aurinia Pharmaceuticals AUPH public float $1.0B, Jun 30, 2025